Pulse Biosciences (PLSE) Liabilities and Shareholders Equity (2015 - 2025)

Pulse Biosciences' Liabilities and Shareholders Equity history runs 11 years deep, the most recent figure standing at $94.5 million for Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 28.63% year-over-year to $94.5 million in Q4 2025; TTM through Dec 2025 was $456.9 million, a 45.01% increase from a year earlier, with the FY2025 full-year figure at $94.5 million, down 28.63% from the prior year.
• Liabilities and Shareholders Equity eased to $94.5 million in Q4 2025 per PLSE's latest filing, from $108.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $133.4 million in Q1 2025 and bottomed at $39.5 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $76.3 million (2022), against an average of $78.7 million.
• Across the five-year window, Liabilities and Shareholders Equity sank 50.92% in 2022 and surged 197.44% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $59.2 million in 2021, then surged by 31.65% to $77.9 million in 2022, then dropped by 24.04% to $59.2 million in 2023, then soared by 123.92% to $132.5 million in 2024, then retreated by 28.63% to $94.5 million in 2025.
• Per Business Quant, the three latest PLSE Liabilities and Shareholders Equity figures stand at $94.5 million (Q4 2025), $108.8 million (Q3 2025), and $120.3 million (Q2 2025).